INTRODUCTION
More than 100 cases of granulocyte colony-stimulating factor (G-CSF)-producing tumors have been reported for various kinds of malignancies (Fig. 1) . However, only a few cases of G-CSF-producing gastric cancer have been reported in the English literature (1, 2) .
In most cases, for all types of malignancies, G-CSF-producing tumors were detected at an advanced stage, associated with a poor prognosis.
We have observed a case of gastric cancer from the prediagnosis stage when leukocyte count was normal, to the advanced stage with marked leukocytosis. Immunohistochemical analysis revealed expression of G-CSF only in the advanced stage, despite the fact that G-CSF receptor expression was not detected at the advanced stage. Therefore, the direct interaction between G-CSF and its receptor did not appear to influence the rapid progression of the tumor. Rather, it appears that in this case it may be the biological function of G-CSF itself that affected cancer progression.
CASE REPORT
A 77-year-old man was diagnosed with a small benign gastric polyp in the posterior wall of the upper body of the stomach by endoscopy which was performed to elucidate the reason for his anemia (Fig. 2a) . Two months later he underwent a colectomy for transverse colon cancer ( pT3, pN1, M0, Stage 3B), the apparent cause of his anemia. One month after the operation, early type I gastric cancer was detected in the same region as the benign gastric polyp (Fig. 2b) . The tumor was removed by the endoscopic mucosal resection (EMR), because the patient refused gastrectomy. Pathological diagnosis of EMR specimen was a well-differentiated adenocarcinoma with possible invasion to the submucosa. Subsequent endoscopic examination revealed the remnant gastric tumor after EMR. Histological diagnosis of the remnant lesion was a poorly differentiated adenocarcinoma. Two months after EMR, the patient was hospitalized to receive a gastrectomy.
After admission, endoscopic examination revealed an enlarged Borrmann type I gastric cancer in the same region where EMR was performed (Fig. 2c) . Laboratory data showed remarkable leukocytosis (38590/ml; 88% neutrophils) and elevated C-reactive protein (7.2 mg/dl).
The leukocyte count and the amount of C-reactive protein level were normal at the time of EMR (5500/ml and 0.2 mg/dl, respectively). The changes in leukocyte count and the amount of C-reactive protein from the time of EMR to the time of death are shown in Fig. 3 . The level of carcinoembryonic antigen was found to be high at 32.2 ng/ml (normal , 5 ng/ml). A bone marrow puncture biopsy revealed a hypercellular marrow with a marked predominance of cells of the myeloid series. Cytogenetic analysis showed no chromosome abnormalities, including Ph1 chromosome. There were no results suggestive of a severe infection. From these findings, we assumed that the patient had G-CSF producing gastric cancer, although we could not confirm this until the autopsy.
The general condition of the patient deteriorated after hospitalization. Melena, abdominal pain, high fever and a general fatigue became apparent. As a result, the operation was cancelled. The leukocyte count rose to 103220/ml (97% neutrophils). In less than 3 months following admission to hospital, the patient died of multiple organ failure.
The autopsy revealed a huge tumor mass (dimension: 17 Â 13 cm), which had invaded the spleen and pancreas. Liver metastases were recognized in S4 and S5. The huge mass consisted entirely of cancer cells, and it was classified macroscopically as a Borrmann type 3 tumor, which formed a giant ulcer with ridge. Cancer cells with large nucleoli proliferated in a solid pattern, and few glandular structures were detected. Histological diagnosis of the tumor was a poorly differentiated adenocarcinoma. Prominent neutrophilic infiltration was detected partially in the tumor as previously reported (3) .
The specimens obtained at biopsy (EMR) and autopsy were stained following the immunoperoxidase procedure (ABC method). After antigen retrieval in the 0.1 M citrate buffer (pH 6.0) using a Pascal pressurized heating chamber (DAKO A/S, Glostrup, Denmark), the sections were incubated with primary antibodies directed against G-CSF (N-20, goat polyclonal antibody, Santa Cruz Biotech, Santa Cruz, CA, USA) and the G-CSF receptor (S-1284, mouse monoclonal antibody, abcam, Cambridge, UK). Binding of the primary antibodies was detected using biotin-conjugated anti-goat or anti-mouse IgG secondary antibodies (Zymed, South San Francisco, CA, USA), followed by incubation with a peroxidase-conjugated biotin -avidin complex (Vectastain ABC kit, Vector, Burlingame, CA, USA). As a negative control, sections were incubated with nonimmune serum. Color reaction was developed in a 0.02% solution of 
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G-CSF producing gastric cancer 3,3 0 -diaminobenzidine in 0.05 M Tris -HCl buffer (pH 7.2) containing 0.01% H 2 O 2 . Results showed that the well differentiated adenocarcinoma found at EMR (Fig. 4a) was negative for G-CSF (Fig. 4b) . In contrast, the poorly differentiated adenocarcinoma found at autopsy (Fig. 4c) showed positive immunoreactivity for G-CSF in the cytoplasm of cancer cells (Fig. 4d) , but negative reactivity for the G-CSF receptor (Fig. 4e) . Histological analysis of the marrow obtained at autopsy revealed hypercellularity with a marked predominance of cells of the myeloid series (Fig. 4f) .
DISCUSSION
We report a case of G-CSF-producing gastric cancer, which showed rapid progression and pronounced leukocytosis. Jpn J Clin Oncol 2007; 37 (10) 795
The leukocytosis was not detected during the early stage of gastric cancer, but rather appeared at an advanced stage. Histologically, the early stage cancer presented as a welldifferentiated adenocarcinoma, which changed to a poorly differentiated adenocarcinoma at the advanced stage. These findings indicated that such histological changes might influence the acquisition of G-CSF-producing ability and hence rapid progression of the tumor. G-CSF is a glycoprotein that influences the survival, proliferation, and maturation of neutrophils through interaction with a specific receptor (4). G-CSF has also been linked to tumor cell growth in vitro (5). In most cases, G-CSFproducing tumors appear to be advanced, and hence its diagnosis has been associated with extremely poor prognosis. It has been reported that genetically modified G-CSFproducing tumor cells suppressed tumor progression in vivo (6 -8) . In contrast, controversial findings that G-CSF promoted cancer progression have also been reported by others (9 -11) . However, although a link between G-CSFproduction and tumor progression has been suggested, its mechanism has yet to be elucidated.
In a recent study, it was shown that G-CSF could influence the function of T-cells and endothelial cells (12, 13) , as well as neutrophils. Therefore, G-CSF may modify the microenvironment of malignant cells, which may in turn be advantageous for tumor progression. In the present case, gastric cancer cells expressed G-CSF but not G-CSF receptors. Therefore, it is not likely that rapid tumor progression was caused by the direct effect of G-CSF on the tumor itself.
In breast cancer, neutropenia during chemotherapy is a marker associated with a good prognosis (14, 15) . Neutropenia has been shown to enhance innate G-CSF production (16) . Exogenous G-CSF is administrated in the case of febrile neutropenia or grade 4 neutropenia during chemotherapy treatment of breast cancer. However, this increase in G-CSF levels might promote breast cancer progression. Recent studies have revealed the relationship between neutropenia and breast cancer (17) : most breast cancer cells express CXCR4, and the interaction between CXCR4 and its ligand (CXCL12) is crucial for the proliferation and survival of CXCR4-expressing cancer cells. G-CSF down-regulates CXCL12 production; therefore, G-CSF is thought to inhibit breast cancer cell growth via suppression of the interaction between CXCR4 and CXCL12.
In this case, it is possible that the poor prognosis of the G-CSF-producing gastric cancer was dependent on a histological change leading to the formation of more aggressive cancer cells, or on a change in the interstitial cells around the tumor, rather than on a direct interaction between G-CSF and its receptor on the tumor cells.
During the treatment of malignancies, it is possible that massive necrosis of a tumor induces a slight leukocytosis (10 000 -15 000/ml) without any evidence of underlying infection. However, we should recognize that an intense leukocytosis in the absence of infection could be induced by G-CSF produced by the malignancies themselves. Though the acquisition of G-CSF production usually indicates a poor prognosis, this condition is not a contraindication for cancer treatment.
